Authors
Latest:
Dr. Chari on Impact of CAR T Cells in MyelomaAjai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the impact of CAR T-cell therapy in myeloma.
Latest:
Dr. Goy Discusses the Cost of CAR T-Cell TherapyAndre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the cost of chimeric antigen receptor (CAR) T-cell therapy.
Latest:
Dr. Boccia on Managing Adverse Events With CAR T-Cell TherapyRalph Boccia, MD, an oncologist at the Center for Cancer and Blood Disorders, associate clinical professor at Georgetown University, discusses managing adverse events associated with chimeric antigen receptor T-cell therapy.
Latest:
Dr. Cohen Discusses CAR T-Cell Therapy in MCLJonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the use of CAR T-cell therapy in patients with mantle cell lymphoma.
Latest:
Dr. Pulsipher on MRD in Pediatric Patients Treated With CAR T CellsMichael Pulsipher, MD, director of cellular therapy and stem cell transplantation, professor of pediatrics, USC Keck School of Medicine, discusses the role of MRD testing in pediatric patients treated with CAR T-cell therapy.
Latest:
Armin Ghobadi, MD, on Assessing CAR-T Cell Combination TherapiesThe associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.
Latest:
Dr. Summers on Role of CAR T Cells in Pediatric CancerCorinne Summers, MD, pediatric oncologist, Seattle Children's Hospital, assistant member, Clinical Research Division, University of Washington Fred Hutchinson Cancer Research Center, discusses the role of CAR T cells in pediatric cancer.
Latest:
Dr. Grupp on the Optimal Setting of CAR T-Cell Therapy in ALLStephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the placement of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with acute lymphoblastic leukemia (ALL).
Latest:
Park Touts Further Developments, Unmet Needs With CAR T-Cell Therapy in ALLJae H. Park, MD, discusses the challenges in using CAR T-cell therapy in adult patients with acute lymphoblastic leukemia, and also highlights the potential role for off-the-shelf CAR T cells.
Latest:
Emerging Car T Therapies in Hematologic Malignancies: Jae H. Park, MDThe hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed emerging CAR T-cell therapies in hematologic malignancies.
Latest:
Dr. Kambhampati on the Potential of CAR T-Cell Therapy in CLLSuman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL).
Latest:
Dr. Lekakis on Managing the Toxicity of CAR T-Cell TherapyLazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses managing the toxicity of CAR T-cell therapy.
Latest:
Dr. Nimer on CAR T-Cell Therapy in Hematologic MalignanciesStephen D. Nimer, MD, professor of medicine, director, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.
Latest:
Safety of Frontline Durvalumab Combo Confirmed in Extensive-Stage Small Cell Lung CancerFew immune-mediated adverse events were observed with frontline durvalumab plus platinum-based therapy and etoposide in patients with extensive-stage small cell lung cancer, and no treatment-emergent antidrug antibodies were elicited by the PD-L1 inhibitor, according to an analysis of the phase III CASPIAN trial reported at the 2019 ESMO Immuno-Oncology Congress.
Latest:
Dr. Adusumilli on the Rationale for Mesothelin-Targeted CAR T-Cell TherapyPrasad S. Adusumilli, MD, surgeon, deputy chief of Thoracic Service, co-director of the Mesothelioma Program, head of Solid Tumors Cell Therapy, Cellular Therapeutics Center, at Memorial Sloan Kettering Cancer Center, discusses the rationale for an autologous mesothelin-targeted CAR T-cell therapy in advanced solid tumors.
Latest:
Dr. Duncan on the Expansion of CAR T-Cell TherapyChristine N. Duncan, MD, a senior physician at Dana-Farber Cancer Institute, and assistant professor of pediatrics, Harvard Medical School, discusses the expansion of CAR T-cell therapy in oncology.
Latest:
Dr. Galal on Managing AEs Linked With CAR T-Cell TherapyAhmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the management of adverse events (AEs) associated with CAR T-cell therapy.
Latest:
Dr. Banna on the Potential for CAR T-Cell Therapy in Lung CancerGiuseppe L. Banna, MD, consultant, Medical Oncology, Cannizzaro Hospital, discusses the potential for CAR T-cell therapy in the treatment of patients with lung cancer.
Latest:
Dr. Sweetenham on Unanswered Questions With CAR T-Cell Therapy in Pediatric ALLJohn Sweetenham, MD, associate director for clinical affairs, Harold G. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses unanswered questions with CAR T-cell therapy in pediatric acute lymphoblastic leukemia.
Latest:
Dr. Maziarz on Unanswered Questions With CAR T-Cell Therapy in DLBCLRichard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma.
Latest:
Mazyar Shadman, MD, on Growing Research Trends in LBCLThe associate professor at Fred Hutch Cancer Center discussed trends he observed in the field in 2023 and at ASH 2023.
Latest:
Navigating CAR T-Cell Therapy Referrals: Bijal Shah, MD; Michael Wang, MDThe hematologists from Moffitt Cancer Center and University of Texas MD Anderson Cancer Center discussed navigating the referral process for CAR T-cell therapy in hematologic malignancies.
Latest:
Dr. Sehgal on the Structure and Manufacturing Process of CAR T CellsAlison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.
Latest:
Targeting CD19 With CAR T in R/R DL B-Cell Lymphoma: Brian T. Hill, MD, PhD; Mazyar Shadman, MD, MPHDoctors from University of Washington and Cleveland Clinic discussed targeting CD19 in CAR T-cell therapy for relapsed/refractory DLBCL.
Latest:
FasTCAR Cell Therapy Granted Orphan Drug Designation for Multiple MyelomaThe designation follows durable responses seen in a phase 1 study of the agent.
Latest:
Dr. Sehgal on the Clinical Implications of CAR T-Cell Therapy in DLBCLAlison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).
Latest:
Dr. Hou on the Latest Updates With CAR T-Cell Therapy in DLBCLJing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the latest updates with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).
Latest:
Outpatient CAR T-Cell Therapy Found Safe, Effective in Large B-Cell LymphomaCarlos R. Bachier, MD, discusses the use of CAR T-cell therapy in the outpatient setting. He also shared insight on the evolving paradigm of graft-versus-host disease.
Latest:
Dr. Mei on Investigational CAR T-Cell Therapies and Antibody-Drug Conjugates in Hodgkin LymphomaMatthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.
Latest:
Axi-cel as Frontline Therapy for High-Risk Large B-cell Lymphoma Produces Encouraging ResponsesIn 37 evaluable patients, the objective response rate in the study was 89% (95% CI, 75%-97%) with complete responses in 78%.
